Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report

Feldman, 2007, Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease, J Neurol Neurosurg Psychiatry, 78, 1056, 10.1136/jnnp.2006.099424 Figiel, 2008, A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders, Curr Med Res Opin, 24, 157, 10.1185/030079908X260961 Frampton, 2014, Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia, Drugs Aging, 31, 639, 10.1007/s40266-014-0197-x Thompson, 2004, The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease, Expert Opin Drug, 3, 425, 10.1517/14740338.3.5.425 Inglis, 2002, The tolerability and safety of cholinesterase inhibitors in the treatment of Dementia, Int J Clin Pract, 127, 45 Dhikav, 2013, Acute dystonic reaction with rivastigmine, Int Psychogeriatr, 25, 1385, 10.1017/S104161021300029X Farlow, 2011, Transdermal patches for the treatment of neurologic conditions in elderly patients: a review, Prim Care Companion CNS Disord, 13, 1 Guay, 2008, Rivastigmine transdermal patch: role in the management of Alzheimer's Disease, Consult Pharm, 23, 598, 10.4140/TCP.n.2008.598 Rösler, 2002, The efficacy of cholinesterase inhibitors in treating the behavioral symptoms of dementia, Int J Clin Pract, 127, 20 Rodda, 2009, Are cholinesterase inhibitors effective in the management of the behavioral and psychologicalsymptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine, Int Psychogeriatr, 21, 813, 10.1017/S1041610209990354 Takeda, 2006, A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease, Int J Geriatr Psychiatry, 21, 17, 10.1002/gps.1402 Robert, 2002, Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine, Curr Med Res Opin, 18, 156, 10.1185/030079902125000561 Lin, 2006, The occipital white matter lesions in Alzheimer's disease patients with visual hallucinations, Clin Imaging, 30, 388, 10.1016/j.clinimag.2006.09.025 Bullock, 2002, Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series, Curr Med Res Opin., 18, 258, 10.1185/030079902125000813 Sobow, 2007, Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series, Neurol Neurochir Pol, 41, 276